New-onset diabetes after transplantation

Current Diabetes Reports

Volumn 5, Issue 4, 2005, Pages 300-304

  Pavlakis, Martha ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; INSULIN; INSULIN LISPRO; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; ROSIGLITAZONE; TACROLIMUS; THYMOCYTE ANTIBODY;

BLOOD GLUCOSE MONITORING; CLINICAL PROTOCOL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; TREATMENT OUTCOME;

EID: 24644462450     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0027-y     Document Type: Review

References (22)

1. Kasiske B, Snyder J, Gilbertson D, Matas A: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
2. Woodward RS, Schnitzler MA, Baty J, et al.: Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3:590-598.
3. American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(suppl 1):85.
4. Miles AM, Sumrani N, Horowitz R, et al.: Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998, 65:380-384.
5. Ducloux D, Kazory A, Chalopin JM: Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005, 79:438-443.
6. Lentine KL, Brennan DC, Schnitzler MA: Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005, 16:496-506.
7. Sumrani NB, Delaney V, Ding ZK, et al.: Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991, 51:343-347.
8. Bloom R, Rao V, Weng F, et al.: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 13:1374-1380.
9. Cho YM, Park KS, Jung HS, et al.: High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care 2003, 26:1123-1128.
10. De Mattos A, Olyaei AJ, Prather J, et al.: Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 2005, 67:714-720.
11. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997, 99:414-423.
12. Tayek JA, Katz J: Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relzationship to serum cortisol. Am J Physiol 1997, 272:E476-E484.
13. Fowelin J, Attvall S, Von Schenck H, et al.: Combined effect of growth hormone and cortisol on late posthypoglycemic insulin resistance in humans. Diabetes 1989, 38:1357-1364.
14. Yale JF, Roy RD, Grose M, et al.: Effects of cyclosporine on glucose tolerance in the rat. Diabetes 1985, 34:1309-1313.
15. Uchizono Y, Iwase M, Nakamura U, et al.: Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004, 145:2264-2272.
16. Drachenberg CB, Klassen DK, Weir MR, et al.: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999, 68:396-402.
17. Pirsch JD, Miller J, Deierhoi MH, et al.: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997, 63:977-983.
18. Gonwa T, Johnson C, Ahsan N, et al.: Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003, 75:2048-2053.
19. Sollinger H: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61:1029-1037.
20. Berg CE, Lavan B, Rondinone CM: Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Comm 2002, 293:1021-1027.
21. Davidson J, Wilkinson A, Dantal J, et al.: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75(10 suppl):SS3-S24.
22. Benhamou PY, Penfornis A: Natural history, prognosis and management of transplantation-induced diabetes mellitus. Diabetes Metab 2002, 28:166-175.